Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

NIH 2INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasms 38Melanoma 36Carcinoma, Non-Small-Cell Lung 16Colorectal Neoplasms 10Pancreatic Neoplasms 5Neoplasm Metastasis 4Glioma 4Triple Negative Breast Neoplasms 3Skin Neoplasms 3Multiple Myeloma 3Lung Neoplasms 3Biliary Tract Neoplasms 3Thyroid Neoplasms 2Rectal Neoplasms 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Oligodendroglioma 2Neurofibroma, Plexiform 2Neurocytoma 2Neuroblastoma 2Leukemia, Myeloid, Acute 2Histiocytosis, Langerhans-Cell 2Glioblastoma 2Ganglioneuroma 2Ganglioglioma 2Colonic Neoplasms 2Brain Neoplasms 2Astrocytoma 2Advanced Solid Tumors 2Adenocarcinoma of Lung 2Uveal Melanoma 1

Interventions

Gemcitabine 11Cisplatin 10pembrolizumab 7Fluorouracil 3Drug Therapy 3spartalizumab 2derazantinib 2Leucovorin 2trametinib 1tislelizumab 1silmitasertib 1seribantumab 1pertuzumab 1olutasidenib 1galactomannan 1exatecan 1durvalumab 1becatecarin 1Tegafur 1Standard of Care 1S 1 (combination) 1Ritonavir 1Quality of Life 1Patient Reported Outcome Measures 1Oxaliplatin 1Observation 1Nivolumab 1Molecular Diagnostic Techniques 1Microscopy, Confocal 1Melphalan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Bile Duct Neoplasms × trametinib × Clear all
NCT05874414 2026-05-14

Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma

Genfit

Phase 1/2 Recruiting
74 enrolled
Gastrointestinal

Bile Duct Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡